Key Takeaways
- Eli Lilly is committing $3 billion to China expansion throughout the next ten years
- The capital will fund orforglipron manufacturing, an oral GLP-1 medication for weight management
- China’s regulatory authorities received Lilly’s marketing application for orforglipron in late 2025
- Bernstein maintains Outperform stance with $1,300 price objective; shares currently near $1,008
- LillyConnect debut enables companies to tailor GLP-1 benefits for workers through partnerships with GoodRx and Cost Plus Drugs
On Wednesday, Eli Lilly ($LLY) revealed plans for a $3 billion capital deployment across China spanning the coming decade. This strategic initiative focuses on establishing production infrastructure for orforglipron, the pharmaceutical giant’s oral once-daily medication designed to address type-2 diabetes and weight management challenges.
Through a WeChat statement, the pharmaceutical company disclosed that it had already filed a marketing authorization request for orforglipron with Chinese regulatory authorities in late 2025. The submission remains under active regulatory assessment.
Unlike Lilly’s current injectable medications such as Zepbound, orforglipron represents a non-peptide GLP-1 receptor agonist with a distinct mechanism. Clinical data from advanced-stage trials demonstrated that overweight participants without diabetes experienced mean weight reduction of 12.4% throughout a 72-week period when administered the maximum dosage.
Additional research revealed that orforglipron successfully supported continued weight management when patients transitioned from Zepbound or Novo Nordisk’s Wegovy. This finding holds strategic importance as Lilly pursues expansion within the oral GLP-1 therapeutic segment.
The China expansion strategy includes establishing domestic manufacturing capabilities and supply chain infrastructure specifically for oral solid dosage medications. This approach would minimize import dependencies while optimizing regional distribution networks.
Lilly’s announcement aligns with broader industry patterns, as other Western pharmaceutical and healthcare companies including Haleon and AstraZeneca have unveiled comparable China-focused expansion initiatives during 2025.
The announcement’s timing carries significance—it precedes an anticipated diplomatic summit between U.S. President Donald Trump and Chinese President Xi Jinping scheduled for this month.
However, not all pharmaceutical companies share this China expansion trajectory. Bristol-Myers Squibb announced in September its agreement to divest a 60% ownership position in a Chinese pharmaceutical joint venture, which included a Shanghai-based production facility.
Bernstein Maintains $1,300 Price Objective
This week, Bernstein SocGen confirmed its Outperform recommendation alongside a $1,300 price objective for LLY stock, citing recent developments in U.S. GLP-1 distribution channels. Shares currently trade near $1,008.
The investment firm emphasized recent CMS guidance regarding the BALANCE model, establishing a $245 Medicaid pricing baseline for obesity medications beginning May 2026, with Medicare expansion commencing July 2026. The comprehensive program spans January 2027 through 2031—reaching beyond the current administration’s term.
According to Bernstein, this extended timeframe delivers pricing stability for Lilly through semaglutide’s patent expiration in 2031.
LillyConnect Platform and Prescription Metrics
Last week witnessed Lilly’s introduction of LillyConnect, an innovative platform enabling employers to establish dedicated GLP-1 insurance benefits for their workforce. The initiative includes collaborations with 15 program administrators, featuring GoodRx and Mark Cuban’s Cost Plus Drugs, alongside two pharmacy partners: CentreWell and HealthDyne.
Through this platform, employers gain flexibility to structure coverage parameters and implement cost-sharing arrangements, potentially reducing out-of-pocket expenses versus direct cash payment alternatives.
Morgan Stanley, maintaining an Overweight rating with a $1,313 objective, characterized the platform introduction favorably. Deutsche Bank similarly holds a Buy recommendation with a $1,285 target.
Prescription data showed Mounjaro recorded approximately 724,500 total prescriptions during the week concluded February 27, representing an increase from the preceding week. Deutsche Bank identified a 7% sequential week-over-week recovery in aggregate GLP-1 prescriptions.
Morgan Stanley observed that supply limitations had constrained Mounjaro sales performance in Brazil, though noted that February’s substantial import increase signals improving product availability.
